Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
This product is intended solely for in vitro and in vivo laboratory research use
This is an effort where industry and academia need to closely collaborate to find the right patient cohorts, which is not an easy task in rare disease. Meanwhile, he wants clinicians to know that tirzepatide is a good option for treating obesity, hyperphagia, MASLD, and type 2 diabetes in AS, but because of the rapid therapeutic response it produces, patients require careful monitoring
The proportions of those with employer-sponsored insurance eligible at different cutoffs of BMI were estimated using only respondents with unredacted values for height and weight and extrapolated to the entire obese population
Carrying excess weight affects far more than cardiovascular health or blood sugar levels
Key Point: Foundayo (orforglipron) launched April 1, 2026 at $149$349 per month self-pay through LillyDirect depending on dose, with eligible commercially insured patients paying as little as $25 per month with a savings card